胃癌患者免疫抑制因子和淋巴细胞亚群变化的临床实验研究  

Clinicoexperimental Study on Immunosuppressive Factors and Lymphocyte Subpopulations in Patients with Gastric Cancer

作　　者：钟述猷[1] 寿松涛[1] 阮大宝[1] 刘政[1] 陈新诚[1] 王鹏志[2] 任毅[2] 

机构地区：[1]天津医学院附属医院免疫实验中心,300052 [2]天津医学院附属医院外科,300052

出　　处：《天津医药》1992年第12期707-710,共4页Tianjin Medical Journal

摘　　要：本文通过T细胞增殖抑制实验发现胃癌患者血清存在免疫抑制因子,可抑制正常人或胃癌患者PBMC对PHA的增殖效应;首次发现不同癌瘤来源的抑制因子有非特异性交叉抑制作用。实验表明胃癌血清抑制因子可诱导/活化正常人Ts(CD_8^+)细胞,使其发挥免疫抑制效应。观察到术后1年以上恢复期患者血清免疫抑制效应明显下降(P<0.001)。本文同时检测了胃癌、胃或十二指肠溃疡患者及正常人群的淋巴细胞亚群,证明进展期胃癌CD_4^+下降,CD_8^+升高明显,CD_4^+/CD_8^+比值显著下降(P<0.001);胃癌术后1月内淋巴细胞亚群与术前无明显差异,而术后半年以上恢复期患者该三项指标趋于正常。It was found that the immunosuppressive factors of gastric cancer could inhibitPBMC to PHA proliferation effect with normal or gastric cancer through T-lympho-cyte proliferation and inhibition experiments. The suppressive factors derived fromdifferent tumors had nonspecific cross inhibition function. It was suggested that thesuppressive factors could induce or activate the immunosuppressive effect of normalTs(CD8^+) cells. Decreased sera immunosuppressive effect after operation over a yearwas also observed, (P<0.001), with lymphocyte subpopulations investigated. The re-sults, an increase in CD8^+, a decrease in CD4^+ and in CD4^+/CD8^+ ratio(P<0.001) werefound in preoperative patients with the cancer, There were not any differences withinone month after operation, but the parameters tended to become normal over half a year.

关 键 词：免疫抑制因子 淋巴细胞亚群 胃肿瘤 

分 类 号：R735.2[医药卫生—肿瘤]